Caris Life Sciences Reports Strong Q4 & FY25 Results, Positive 2026 Outlook, and MCED Test Progress

summarizeSummary

Caris Life Sciences announced robust Q4 and full year 2025 financial results, including a return to Q4 net income and nearly 100% full-year revenue growth, alongside strong 2026 guidance and progress on its multi-cancer early detection test.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Results

  Caris Life Sciences reported Q4 2025 total revenue of $292.9 million, a 125% increase year-over-year, and full year 2025 total revenue of $812.0 million, a 97% increase. The company achieved net income of $82.0 million in Q4 2025, a significant turnaround from a net loss in the prior year, and reduced its full-year net loss to $68.1 million from $281.9 million in 2024. Adjusted EBITDA and operating cash flow were positive for both the quarter and full year 2025.

• Positive 2026 Financial Outlook and Guidance

  The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to full year 2025. Clinical therapy selection volume is projected to grow approximately 20%, and the company anticipates remaining positive on Free Cash Flow and Adjusted EBITDA.

• Advancement of Multi-Cancer Early Detection (MCED) Test

  Caris Life Sciences announced the completion of the interim readout of its Achieve 1 study, which supports the upcoming launch of Caris Detect, its multi-cancer early detection (MCED) test, in the first half of 2026. This represents a significant pipeline advancement and potential future growth driver.

auto_awesomeAnalysis

Caris Life Sciences has reported exceptionally strong financial results for Q4 and full year 2025, demonstrating significant revenue growth and a notable shift towards profitability and positive cash flow. The company's Q4 2025 net income of $82.0 million marks a substantial improvement from a net loss in the prior year, and full-year revenue nearly doubled. The positive 2026 revenue guidance of $1.0 billion to $1.02 billion, representing 23% to 26% growth, provides a strong forward-looking signal. This definitive report follows preliminary results announced on January 12, 2026, providing investors with finalized figures and a clear outlook. Additionally, the progress on the Caris Detect multi-cancer early detection test, with an interim readout completed and a planned H1 2026 launch, indicates a significant future growth opportunity.